Zentalis Pharmaceuticals, Inc. (ZNTL) Stock Score, Valuation & Financial Research

Zentalis Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ZNTL

Zentalis Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.67. These figures are a research snapshot, not a buy or sell recommendation.

What Zentalis Pharmaceuticals, Inc. does

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. The company has not yet generated revenue from product sales and currently relies on capital raises and potential future milestone payments or licensing arrangements to fund its research and development activities.

Products and services

  • The company is developing a pipeline of oncology candidates, with its lead investigational product being azenosertib, a WEE1 inhibitor currently in clinical trials for various cancer indications including ovarian cancer.

Brands and product families

  • Zentalis — Corporate brand name. Source

Customer types

Clinical trial sites and patients.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its drug candidates for clinical trials; specific supplier names are not disclosed. Source

Business strengths to evaluate

  • Proprietary Integrated Discovery Engine Source

Business risks and research considerations

  • History of operating losses and lack of revenue Source
  • Dependence on clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ZNTL financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.67
Market capitalization:
190.07M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -174.9M
Free cash flow:
USD -125.25M
Cash:
USD 24.78M
Total debt:
USD 37.69M
EPS:
USD -2.46

What stands out

  • Free cash flow is USD -125.25M, negative for the stored period.
  • The balance sheet shows USD 24.78M of cash versus USD 37.69M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 12.91M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ZNTL

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ZNTL fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does ZNTL's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for ZNTL to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of ZNTL's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ZNTL

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.